文献速递浆细胞疾病造血干细胞移植与细胞治疗

一种用于治疗多发性骨髓瘤的BCMA/CD16A双特异性先天免疫细胞衔接器

A BCMA/CD16A bispecific innate cell engager for the treatment of multiple myeloma.
PubMed 文献 · Leukemia · 2022-01-10

RO7297089是一种新型靶向BCMA/CD16A的双特异性先天免疫细胞衔接器,通过高亲和力结合CD16A并重定向NK细胞细胞毒性和巨噬细胞吞噬作用诱导BCMA阳性多发性骨髓瘤细胞裂解。其选择性靶向CD16A而不结合其他Fcγ受体,活性受竞争性IgG影响较小,在临床前研究中表现出比传统抗体更强的肿瘤杀伤能力,且食蟹猴毒理学数据显示安全性良好。

要点

  • RO7297089选择性靶向CD16A,不结合中性粒细胞上的CD16B,且不受158V/F多态性影响
  • RO7297089诱导肿瘤细胞杀伤比传统抗体(野生型和Fc增强型)更有效
  • 临床前毒理学显示体外细胞因子释放极少,食蟹猴中无RO7297089相关死亡或不良事件

核心结论

  • RO7297089的数据提示其耐受性良好,并具有成为多发性骨髓瘤患者新型有效治疗方法的潜力。

研究设计与样本

  • 临床前研究,包括结构分析、体外杀伤实验和食蟹猴毒理学评估。

主要发现

  • RO7297089通过高亲和力结合CD16A并重定向NK细胞细胞毒性和巨噬细胞吞噬作用诱导BCMA阳性多发性骨髓瘤细胞裂解。
  • RO7297089选择性靶向CD16A,不结合其他Fcγ受体(包括中性粒细胞上的CD16B),且不受158V/F多态性影响。
  • RO7297089活性受竞争性IgG影响较小,提示在M蛋白存在时仍有活性。
  • 结构分析显示这是由于选择性结合CD16A上Fc结合位点对面 uniquely 存在的单个残基(Y140)。
  • RO7297089诱导肿瘤细胞杀伤比传统抗体(野生型和Fc增强型)更有效,并在极低效靶比下诱导BCMA阳性细胞裂解。

关键数值与推荐

  • RO7297089选择性靶向CD16A,不结合其他Fcγ受体(包括CD16B),且不受158V/F多态性影响。
  • RO7297089诱导肿瘤细胞杀伤比传统抗体(野生型和Fc增强型)更有效。
  • RO7297089在极低效靶比下诱导BCMA阳性细胞裂解。
  • 体外细胞因子释放极少,食蟹猴中未观察到RO7297089相关死亡或不良事件。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Despite the recent progress, multiple myeloma (MM) is still essentially incurable and there is a need for additional effective treatments with good tolerability. RO7297089 is a novel bispecific BCMA/CD16A-directed innate cell engager (ICE®) designed to induce BCMA+ MM cell lysis through high affinity binding of CD16A and retargeting of NK cell cytotoxicity and macrophage phagocytosis. Unlike conventional antibodies approved in MM, RO7297089 selectively targets CD16A with no binding of other Fcγ receptors, including CD16B on neutrophils, and irrespective of 158V/F polymorphism, and its activity is less affected by competing IgG suggesting activity in the presence of M-protein. Structural analysis revealed this is due to selective interaction with a single residue (Y140) uniquely present in CD16A opposite the Fc binding site. RO7297089 induced tumor cell killing more potently than conventional antibodies (wild-type and Fc-enhanced) and induced lysis of BCMA+ cells at very low effector-to-target ratios. Preclinical toxicology data suggested a favorable safety profile as in vitro cytokine release was minimal and no RO7297089-related mortalities or adverse events were observed in cynomolgus monkeys. These data suggest good tolerability and the potential of RO7297089 to be a novel effective treatment of MM patients.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Kakiuchi-Kiyota S, Ross T, Wallweber HA, et al. A BCMA/CD16A bispecific innate cell engager for the treatment of multiple myeloma. Leukemia. 2022. PMID: 35001074. doi:10.1038/s41375-021-01478-w

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。